Special Issue "Vaccines as Allies in the Malaria Eradication Effort"
Deadline for manuscript submissions: 31 March 2019
Dr. Elke S. Bergmann-Leitner
US Military Malaria Research Program, Malaria Vaccine Branch, Silver Spring, USA
Interests: immune escape mechanisms; immune correlates of protection; vaccine design; assay development for vaccine evaluation; immunomodeling
Malaria remains a major global health threat, with 216 million cases of malaria worldwide and approx. 445,000 deaths per year, despite massive elimination efforts. Increasing resistance of Plasmodium against anti-malarial drugs and decreasing effectiveness of insecticides are currently among the greatest challenges facing the eradication campaign. The development of an efficacious malaria vaccine that reduces—at minimum—mortality rates, has been a focal point of malaria research. While there are vaccine candidates that show promising short-term vaccine efficacy, longevity of protection and cross-reactivity against strains different from the vaccine strain remain elusive. Current efforts to generate an efficacious vaccine range from testing different vaccine platforms to including various vaccine antigens that are targeted because they are crucial for the survival and/or functionality of the parasite. In addition, while pre-erythrocytic and blood-stage based vaccines intended to prevent or alleviate disease, promising transmission blocking vaccines are being developed, which are considered altruistic vaccines since they contribute to malaria eradication at the population level, but do not directly benefit the vaccinee. This Special Issue will provide an overview over the strategies targeting different life stages of Plasmodium, application of different vaccine platforms and regimens to increase vaccine efficacy, summarizing the state-of-the-art in the field of malaria vaccine research.Dr. Elke S. Bergmann-Leitner
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 350 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune correlate
- life stage
- vaccine antigens
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Author: Pedro Cravo